We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Webinar Recordings » Expediting the Generic Drug Approval Process - Webinar Recording/Transcript

Other Options

Audio Recording/Transcript - Dec. 6, 2018

$287.00

Audio Recording/Transcript - Dec. 6, 2018

$258.00

Audio Recording/Transcript - Dec. 6, 2018

$244.00

Audio Recording/Transcript - Dec. 6, 2018

$230.00

Audio Recording/Transcript - Dec. 6, 2018

$215.00

Expediting the Generic Drug Approval Process - Webinar Recording/Transcript

$287.00
Webinar Recordings

Product Details

Expediting the Generic Drug Approval Process: FDA’s New Initiatives on Drug Competition

The FDA announced its Drug Competition Action Plan a year ago. And the agency continues to announce new guidances intended to speed up generic drug approvals. The FDA recently announced a guidance to enhance filing review requirements.

A record number of generic drugs have been approved this year. With the new expediting process, Commissioner Gottlieb believes that record highs will be achieved year on year.

Are you — and your new generic — ready for the expedited pathway?

In 90 fast-paced minutes attorneys Chad Landmon and Suchira Ghosh of Axinn, Veltrop & Harkrider LLP will methodically lay out the various policies, how they’ve been implemented, how you can engage with them and identify possible issues. You’ll learn the following:

  • The new pathways to expedite approval of generic drug applications, including 180-day exclusivity
  • Best practices to obtain exclusivity and the top don’ts for losing exclusivity
  • Recent FDA policy statements and guidance on generic drugs and their impact on regulatory and quality professionals
  • Substantive changes to REMS standards that impact ANDAs
  • FDA’s other policy initiatives: prioritizing generic drug review; spur generic approvals to increase competition and lower cost, while maintaining quality
  • How the real cost saving benefit provided by generics doesn’t come into full effect until there are multiple generic versions available

Order today to gain a clearer understanding of the various FDA initiatives surrounding generic drug access and how to best navigate these changes.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing